1: Kuoppamäki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. J Neural Transm (Vienna). 2015 Dec;122(12):1709-14. doi: 10.1007/s00702-015-1449-6. Epub 2015 Sep 7. PubMed PMID: 26347184; PubMed Central PMCID: PMC4644189.

2: Li LS, Liu CZ, Xu JD, Zheng LF, Feng XY, Zhang Y, Zhu JX. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease. World J Gastroenterol. 2015 Mar 28;21(12):3509-18. doi: 10.3748/wjg.v21.i12.3509. PubMed PMID: 25834315; PubMed Central PMCID: PMC4375572.

3: Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K. Pooled analysis of phase III with entacapone in Parkinson's disease. Acta Neurol Scand. 2014 Oct;130(4):239-47. doi: 10.1111/ane.12278. Epub 2014 Sep 3. PubMed PMID: 25186800.

4: Alqahtani S, Kaddoumi A. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability. Biopharm Drug Dispos. 2015 Dec;36(9):587-602. doi: 10.1002/bdd.1986. PubMed PMID: 26295926.

5: Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J. Entacapone and prostate cancer risk in patients with Parkinson's disease. Mov Disord. 2015 Apr 15;30(5):724-8. doi: 10.1002/mds.26140. Epub 2015 Jan 16. PubMed PMID: 25639262.

6: Hsu A, Yao HM, Gupta S, Modi NB. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). J Clin Pharmacol. 2015 Sep;55(9):995-1003. doi: 10.1002/jcph.514. Epub 2015 May 20. PubMed PMID: 25855267; PubMed Central PMCID: PMC5032972.

7: Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol. 2014 Sep;70(9):1059-71. doi: 10.1007/s00228-014-1701-2. Epub 2014 Jun 14. PubMed PMID: 24925090.

8: Kaphzan H, Ben-Shachar D, Klein E. Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. Int J Neuropsychopharmacol. 2014 Feb;17(2):337-40. doi: 10.1017/S1461145713001387. Epub 2013 Nov 12. PubMed PMID: 24229565.

9: Lv X, Wang XX, Hou J, Fang ZZ, Wu JJ, Cao YF, Liu SW, Ge GB, Yang L. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases. Toxicol Appl Pharmacol. 2016 Jun 15;301:42-9. doi: 10.1016/j.taap.2016.04.009. Epub 2016 Apr 16. PubMed PMID: 27089846.

10: Alshammari TM, AlMutairi EN. Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database. Saudi Pharm J. 2015 Jan;23(1):28-32. doi: 10.1016/j.jsps.2014.04.005. Epub 2014 Apr 30. PubMed PMID: 25685040; PubMed Central PMCID: PMC4311018.

11: Tambasco N, Muti M, Chiarini P, Tarducci R, Caproni S, Castrioto A, Nigro P, Parnetti L, Floridi P, Rossi A, Calabresi P. Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study. PLoS One. 2014 May 15;9(5):e96806. doi: 10.1371/journal.pone.0096806. eCollection 2014. PubMed PMID: 24830331; PubMed Central PMCID: PMC4022515.

12: Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec;20(12):1335-40. doi: 10.1016/j.parkreldis.2014.08.004. Epub 2014 Aug 15. PubMed PMID: 25306200.

13: Longo DM, Yang Y, Watkins PB, Howell BA, Siler SQ. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):31-9. doi: 10.1002/psp4.12053. Epub 2016 Jan 13. PubMed PMID: 26844013; PubMed Central PMCID: PMC4728295.

14: Madias JE. Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome. Parkinsonism Relat Disord. 2015 Apr;21(4):426. doi: 10.1016/j.parkreldis.2014.11.011. Epub 2014 Nov 20. PubMed PMID: 25443553.

15: Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, Pinheiro SP, Macurdy TE, Shih D, Worrall C, Kelman JA. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. Mov Disord. 2013 Apr;28(4):490-7. doi: 10.1002/mds.25351. Epub 2013 Feb 26. PubMed PMID: 23443994.

16: Baldacci F, Vergallo A, Del Dotto P, Ulivi M, Palombo C, Casolo G, Bonuccelli U. RE response to: "Entacapone, Parkinson's disease, "functional adrenergic denervation", and Takotsubo syndrome". Parkinsonism Relat Disord. 2015 Apr;21(4):427. doi: 10.1016/j.parkreldis.2014.11.010. Epub 2014 Nov 20. PubMed PMID: 25630888.

17: Kocer B, Guven H, Comoglu SS. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective? Biomed Res Int. 2016;2016:7563705. doi: 10.1155/2016/7563705. Epub 2016 Jul 17. PubMed PMID: 27493964; PubMed Central PMCID: PMC4967439.

18: Li LS, Zheng LF, Xu JD, Ji T, Guo H, Li XF, Li Y, Zhang Y, Zhu JX. Entacapone promotes cAMP-dependent colonic Cl(-) secretion in rats. Neurogastroenterol Motil. 2011 Jul;23(7):657-e277. doi: 10.1111/j.1365-2982.2011.01715.x. Epub 2011 Apr 19. PubMed PMID: 21501335.

19: Ribeiro RP, Gasparetto JC, de Oliveira Vilhena R, Guimarães de Francisco TM, Martins CA, Cardoso MA, Pontarolo R, de Carvalho KA. Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method. Bioanalysis. 2015;7(2):207-20. doi: 10.4155/bio.14.230. Erratum in: Bioanalysis. 2015;7(7):924. de Francisco, Thais Martins Guimarães [corrected to Guimarães de Francisco, Thais Martins]. PubMed PMID: 25587837.

20: Elrington GM. Review on initial drug treatment in Parkinson's disease did not mention entacapone. BMJ. 2015 Nov 3;351:h5843. doi: 10.1136/bmj.h5843. PubMed PMID: 26530214.